Abstract
Rheumatoid arthritis, a chronic degenerative autoimmune disease is hallmarked by tenacious inflammation of synovial membranes causing cartilage destruction and bone erosion. The search for effective therapies to mitigate its degenerative conditions remains partly elusive. Fibroblast growth factor 21 (FGF21) is known to modulate inflammation, playing a significant role in immune-mediated diseases such as rheumatoid arthritis. Here, we histopathologically evaluate the therapeutic efficacy of FGF21 in collagen-induced arthritis (CIA) mice. CIA mice were subcutaneously treated with FGF21 (3 mg/kg) for three consecutive weeks. Arthritic severity was scored followed by histopathological evaluation of the joints and immunohistochemistry using rabbit ant-cathepsin K, IL-10, MMP1, and 3 antibodies. Our data revealed that FGF21 significantly mitigated the severity of arthritis. Histopathologically, the articular structure was considerably enhanced by FGF21 through the reduction in the expression of cathepsin K and MMP3 whiles upregulating the expression of IL-10. Taken together, our findings suggest that FGF21 preserves the integrity of the articular structure thereby preventing cartilage and bone destruction in CIA mice. FGF21, therefore, has therapeutic prospects in the treatment of RA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
